46234-22-4

Upstream product

• 17356-08-0 thiourea 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 813458-02-5 6-methyl-2-(4-methoxybenzylthio)-1,4-dihydropyrimidine-4-methoxymethyl-5-carboxylic acid 3-thiophen-2-ylethylester 
• 813458-01-4 6-methyl-2-(4-methoxybenzylthio)-1,4-dihydropyrimidine-4-p-methoxybenzyloxymethyl-5-carboxylic acid 2-(5-chlorothiophen)-2-ylethyl ester 

Relevant academic research and scientific papers

Structure-activity relationship study of the bacterial actin-like protein MreB inhibitors: Effects of substitution of benzyl group in S-benzylisothiourea

We comprehensively investigated the effects of substitution of the benzyl group in S-benzylisothiourea derivatives on antibacterial activity, because we found previously that some substitutions enhanced it. A 2,4-Cl 2-derivative was found to be the most effective compound, it was stronger than the original one in Gram-negative rod shaped-bacteria such as Escherichia coli and Salmonella typhimurium.

HEPATITIS C VIRUS INHIBITORS

The present invention relates to new compounds useful for the treatment or prevention of hepatitis C, process for preparing them, and a composition for the treatment or prevention of hepatitis C comprising the compounds as an active ingredient.

Substituted 1,4-dihydropyrimidine-5-carboxylate compounds, their preparation and uses

PCT No. PCT/SE98/01207 Sec. 371 Date Oct. 14, 1998 Sec. 102(e) Date Oct. 14, 1998 PCT Filed Jun. 22, 1998 PCT Pub. No. WO99/01437 PCT Pub. Date Jan. 14, 1999There are provided novel compounds of formula (I) including their 3,4-dihydropyrimidine tautomer f